Literature DB >> 22162561

Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains.

Cheol-In Kang1, Yu Mi Wi, Mi Young Lee, Kwan Soo Ko, Doo Ryeon Chung, Kyong Ran Peck, Nam Yong Lee, Jae-Hoon Song.   

Abstract

Limited clinical information is available regarding community onset infections caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. A case-control study was performed to evaluate the epidemiology and risk factors of these types of infections. A case patient was defined as a person whose clinical sample yielded ESBL-producing E. coli. For each case patient, one control was randomly chosen from a group of outpatients from whom non-ESBL-producing E. coli had been isolated and for whom a clinical sample had been sent to the same laboratory for culturing during the following week. Of 108 cases of ESBL-producing E. coli, 56 (51.9%) were classified as health care associated (HCA). Univariate analysis showed male gender, HCA infection, severe underlying illness, and a prior receipt of antibiotics to be associated with ESBL-producing E. coli. In the multivariate analysis, HCA infection (odds ratio [OR], 3.18; 95% confidence interval [CI], 1.67 to 6.06; P < 0.001) and previous use of antibiotics (OR, 4.88; 95% CI, 2.08 to 11.48; P < 0.001) were found to be significantly associated with the ESBL group. In a multivariate analysis that included each antibiotic, previous use of fluoroquinolone (OR, 7.32; 95% CI, 1.58 to 34.01; P = 0.011) was significantly associated with ESBL-producing E. coli. Of 101 isolates in which ESBLs and their molecular relationships were studied, all isolates produced ESBLs from the CTX-M family (CTX-M-14, 40 isolates; CTX-M-15, 39 isolates; and other members of the CTX-M family, 22 isolates). In conclusion, this study confirms that ESBL-producing E. coli strains are a notable cause of community onset infections in predisposed patients. HCA infection and previous use of fluoroquinolone were significant factors associated with ESBL-producing E. coli in community onset infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22162561      PMCID: PMC3264158          DOI: 10.1128/JCM.06002-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

Review 1.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.

Authors:  Johann D D Pitout; Kevin B Laupland
Journal:  Lancet Infect Dis       Date:  2008-03       Impact factor: 25.071

2.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Jesús Rodríguez-Baño; Juan C Alcalá; Jose M Cisneros; Fabio Grill; Antonio Oliver; Juan P Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual
Journal:  Arch Intern Med       Date:  2008-09-22

3.  CTX-M and SHV-12 beta-lactamases are the most common extended-spectrum enzymes in clinical isolates of Escherichia coli and Klebsiella pneumoniae collected from 3 university hospitals within Korea.

Authors:  Jungmin Kim; Yu-Mi Lim; Insoo Rheem; Yeonhee Lee; Je-Chul Lee; Sung-Yong Seol; Yu-Chul Lee; Dong-Taek Cho
Journal:  FEMS Microbiol Lett       Date:  2005-04-01       Impact factor: 2.742

4.  Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.

Authors:  Emily P Hyle; Adam D Lipworth; Theoklis E Zaoutis; Irving Nachamkin; Neil O Fishman; Warren B Bilker; Xiangquin Mao; Ebbing Lautenbach
Journal:  Clin Infect Dis       Date:  2005-03-30       Impact factor: 9.079

5.  In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.

Authors:  Kwan Soo Ko; Ji Yoeun Suh; Kyong Ran Peck; Mi Young Lee; Won Sup Oh; Ki Tae Kwon; Dong Sik Jung; Nam Yong Lee; Jae-Hoon Song
Journal:  Diagn Microbiol Infect Dis       Date:  2007-02-14       Impact factor: 2.803

6.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

Review 7.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

8.  Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.

Authors:  Esther Calbo; Verónica Romaní; Mariona Xercavins; Lucía Gómez; Carolina Garcia Vidal; Salvador Quintana; Jordi Vila; Javier Garau
Journal:  J Antimicrob Chemother       Date:  2006-02-21       Impact factor: 5.790

9.  Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  C-I Kang; H S Cheong; D R Chung; K R Peck; J-H Song; M-D Oh; K-W Choe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-18       Impact factor: 3.267

10.  Long-term survival and function after suspected gram-negative sepsis.

Authors:  T M Perl; L Dvorak; T Hwang; R P Wenzel
Journal:  JAMA       Date:  1995-07-26       Impact factor: 56.272

View more
  31 in total

1.  High prevalence of antimicrobial resistance among common bacterial isolates in a tertiary healthcare facility in Rwanda.

Authors:  Cyprien Ntirenganya; Olivier Manzi; Claude Mambo Muvunyi; Onyema Ogbuagu
Journal:  Am J Trop Med Hyg       Date:  2015-02-02       Impact factor: 2.345

Review 2.  Population-based epidemiology and microbiology of community-onset bloodstream infections.

Authors:  Kevin B Laupland; Deirdre L Church
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

3.  In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia.

Authors:  Min Kyeong Cha; Cheol-In Kang; So Hyun Kim; Sun Young Cho; Young Eun Ha; Yu Mi Wi; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

4.  [Prevalence and risk factors for extended-spectrum β-lactamase-producing Escherichia coli causing community-onset urinary tract infections in Colombia].

Authors:  Victor M Blanco; Juan J Maya; Adriana Correa; Marcela Perenguez; Juan S Muñoz; Gabriel Motoa; Christian J Pallares; Fernando Rosso; Lorena Matta; Yamile Celis; Martha Garzon; María V Villegas
Journal:  Enferm Infecc Microbiol Clin       Date:  2016-01-13       Impact factor: 1.731

5.  Predictors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli infection in a Midwestern community.

Authors:  Ritu Banerjee; Jacob Strahilevitz; James R Johnson; Payal P Nagwekar; Donna M Schora; Ilene Shevrin; Hongyan Du; Lance R Peterson; Ari Robicsek
Journal:  Infect Control Hosp Epidemiol       Date:  2013-07-17       Impact factor: 3.254

6.  Antibiotic Therapy for Acute Watery Diarrhea and Dysentery.

Authors:  David R Tribble
Journal:  Mil Med       Date:  2017-09       Impact factor: 1.437

7.  Molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli in the community and hospital in Korea: emergence of ST131 producing CTX-M-15.

Authors:  Sun Hee Park; Ji-Hyun Byun; Su-Mi Choi; Dong-Gun Lee; Si-Hyun Kim; Jae-Cheol Kwon; Chulmin Park; Jung-Hyun Choi; Jin-Hong Yoo
Journal:  BMC Infect Dis       Date:  2012-06-29       Impact factor: 3.090

Review 8.  Current epidemiology and growing resistance of gram-negative pathogens.

Authors:  David M Livermore
Journal:  Korean J Intern Med       Date:  2012-05-31       Impact factor: 2.884

9.  Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae--a case-control study in a low prevalence country.

Authors:  Arne Søraas; Arnfinn Sundsfjord; Irene Sandven; Cathrine Brunborg; Pål A Jenum
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

10.  Higher Prevalence of Klebsiella pneumoniae Extended-Spectrum β-Lactamase in Patients on Renal Replacement Therapy.

Authors:  Hyang-Lim Lee; Dong-Hee Whang; Dong-Won Park; Young-Jin Lee; Yeong-Hoon Kim; Ho-Jun Chin; Suhnggown Kim; Ho-Seok Koo
Journal:  J Korean Med Sci       Date:  2013-07-31       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.